

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal


Pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating advanced or recurrent endometrial cancer ID6381

Provisional Stakeholder List

| Provisional Consultees | Provisional Commentators (no right to submit or appeal) |
|---|--|
| Company | General |
| Merck Sharp & Dohme (pembrolizumab) <u>Patient/carer groups</u> Black Health Agency for Equality Cancer Black Care Cancer Equality | All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission |
| Cancer 52 Endometriosis UK Eve Appeal Helen Rollason Cancer Charity Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres Marie Curie Peaches Womb Cancer Trust South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care Wollbaing of Women | Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Government Welsh Health Specialised Services Committee |
| Wellbeing of Women Womb Cancer Support UK Women's Health Concern | <u>Possible comparator companies</u> Accord (carboplatin, paclitaxel, cisplatin, doxorubicin) |
| <u>Healthcare professional groups</u> Association of Anaesthetists Association of Cancer Physicians Association of Surgeons of Great Britain and Ireland British Association of Surgical Oncology British Geriatrics Society British Gynaecological Cancer Society British Institute of Radiology British Oncology Pharmacy Association | Alliance Healthcare (cyclophosphamide, paclitaxel) Bausch & Lomb (megestrol acetate) Baxter Healthcare (cyclophosphamide) Bristol Myers Squibb Pharmaceuticals (paclitaxel) Consilient Health (carboplatin) Fresenius Kabi (carboplatin, paclitaxel) Hospira UK (carboplatin, paclitaxel) Janssen-Cilag (doxorubicin) Medac GmbH (doxorubicin) Novartis (cisplatin, cyclophosphamide) |

Provisional stakeholder list for the evaluation of pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating advanced or recurrent endometrial cancer ID6381 Issue date: May 2024

© National Institute for Health and Care Excellence 2024. All rights reserved.



| Provisional Consultees | Provisional Commentators (no right to submit or appeal) |
|--|--|
| British Psychosocial Oncology Society British Society for Clinical Cytology British Society for Colposcopy and Cervical Pathology Cancer Research UK National Forum of Gynaecological Oncology Nurses Royal College of Anaesthetists Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Pathologists Royal College of Pathologists Royal College of Surgeons Royal College of Surgeons Royal College of Surgeons Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Oncology Nursing Society Others Department of Health and Social Care NHS England | Pfizer (carboplatin, paclitaxel, cisplatin, doxorubicin, medroxyprogesterone acetate) Sandoz (cyclophosphamide) Seacross Pharmaceuticals (paclitaxel, doxorubicin) Teva UK (carboplatin, paclitaxel) <u>Relevant research groups</u> Genomics England Institute of Cancer Research MRC Clinical Trials Unit National Institute for Health Research <u>Associated Public Health groups</u> Public Health Wales UK Health Security Agency |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:


<u>Consultees</u>

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Provisional stakeholder list for the evaluation of pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating advanced or recurrent endometrial cancer ID6381 Issue date: May 2024

© National Institute for Health and Care Excellence 2024. All rights reserved.



All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

Consultee or commentator stakeholders are provisional until a CA&U form is signed at appraisal stage.